Geron Corp at Goldman Sachs Healthcare Conference Transcript
Great. Well, thank you so much. We've got -- for everyone who's joining us both here and on the webcast, we've got the team from Geron here, Chip Scarlett, CEO. So maybe let's just start with an overview.
Yes, love to. Thanks a lot for inviting us. I'm glad to be here and look forward to the next 45 minutes or so. Well, first of all, I think -- let me give a thumbnail sketch of the company for people who don't know us. Geron is focused on telomerase inhibition as a novel approach to the treatment of heme malignancies. Telomerase itself is an enzyme that's constitutively upregulated in malignant hematopoietic stem and progenitor cells. These are the cells that are really responsible for these diseases. And both of our Phase III programs in lower-risk MDS and relapsed and refractory MF currently have kind of an interesting and relatively low competitive intensity and very high unmet needs for new innovative therapies.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |